|1.||Lindhofer, Horst: 12 articles (06/2014 - 07/2007)|
|2.||Bokemeyer, Carsten: 7 articles (10/2015 - 08/2010)|
|3.||Jäger, Michael: 7 articles (06/2012 - 07/2007)|
|4.||Wimberger, Pauline: 6 articles (12/2015 - 07/2007)|
|5.||Sehouli, Jalid: 6 articles (09/2015 - 08/2009)|
|6.||Seimetz, Diane: 6 articles (06/2014 - 03/2010)|
|7.||Friccius-Quecke, Hilke: 5 articles (12/2014 - 10/2007)|
|8.||Heiss, Markus M: 5 articles (06/2014 - 09/2010)|
|9.||Ruf, Peter: 4 articles (12/2015 - 05/2010)|
|10.||Pietzner, Klaus: 4 articles (12/2014 - 08/2011)|
02/01/2014 - "Catumaxomab has reached phase III clinical trials and exhibits promise with reports, showing that it can cause a significant and sustained reduction in ascites. "
11/01/2014 - "Catumaxomab prolonged PuFI and TTPu had a beneficial effect on quality of life, as shown by the improvement in ascites symptoms, and had an acceptable safety profile, which is consistent with its mode of action."
06/15/2014 - "OS was significantly improved after catumaxomab treatment in patients with malignant ascites. "
08/06/2007 - "In patients with malignant ascites, catumaxomab significantly increased the paracentesis-free interval, corroborating the high efficacy of this therapeutic antibody. "
09/22/2015 - "Prospective studies with larger patients samples are urgently needed to confirm these findings and studies testing dose-intensified catumaxomab in patients with sEpCAM-positive ascites should be envisaged. "
11/01/2010 - "Efficacy of catumaxomab in tumor spheroid killing is mediated by its trifunctional mode of action."
09/01/2007 - "In this pilot trial we assessed whether cytokine release can be controlled by ex vivo cell opsonization and cytokine wash-out before administration of catumaxomab, preserving its anti-cancer activity. "
07/10/2015 - "Both, the diminished immune reaction and the enhanced epithelial and malignant characteristics of the tumor cells open new avenues for therapeutic options and strategies, like Catumaxomab, already in clinical use."
01/01/2015 - "In addition, we evaluated effects of different sEpCAM concentrations on catumaxomab-dependent cell-mediated cytotoxicity (ADCC) with human peripheral blood mononuclear cells (PBMNCs) and human tumor cells. "
01/01/2011 - "Catumaxomab represents a self-supporting system, as no additional immune cell activation is required for tumor eradication. "
|3.||Ovarian Neoplasms (Ovarian Cancer)
10/01/2011 - "The aim of this study was to select the best catumaxomab regimen for further investigation in ovarian cancer based on confirmed tumour response. "
12/01/2012 - "Extraperitoneal response to intraperitoneal immunotherapy with catumaxomab in a patient with cutaneous lymphangiosis carcinomatosa from ovarian cancer: a case report and review of the literature."
09/01/2013 - "It is very encouraging that different prospective studies from diverse scientific teams recently presented positive results concerning the efficacy and the safety of catumaxomab in the treatment of malignant ascites in patients with ovarian cancer. "
07/01/2007 - "This suggests that catumaxomab is a promising treatment option in ovarian cancer patients with malignant ascites."
01/01/2013 - "In addition, clinical trials exploring the use of catumaxomab in the treatment of malignant ascites in patients with ovarian cancer are reviewed. "
08/01/2009 - "Compared to other reviews, catumaxomab, a new antibody, was presented and the treatment options were focused on ovarian carcinoma patients. "
01/01/2014 - "The aim of this randomized phase II study is to assess 2-year overall survival after complete resection of limited carcinomatosis synchronous with gastric carcinoma, followed by an intraperitoneal infusion of catumaxomab with different total doses administered in each of the 2 arms. "
01/01/2014 - "Treatment of gastric peritoneal carcinomatosis by combining complete surgical resection of lesions and intraperitoneal immunotherapy using catumaxomab."
01/01/2011 - "Immunotherapy of peritoneal carcinomatosis with catumaxomab."
09/01/2010 - "This paper reviews the mode of action of catumaxomab and analyzes different fields of local immunotherapy in patients with peritoneal carcinomatosis. "
|5.||Stomach Neoplasms (Stomach Cancer)
10/01/2015 - "A phase II study of catumaxomab administered intra- and postoperatively as part of a multimodal approach in primarily resectable gastric cancer."
07/09/2012 - "Despite the study not being designed or powered to evaluate overall survival, significant differences favouring the addition of catumaxomab to paracentesis were seen in analyses of the safety population and the subpopulation of patients with gastric cancer. "
01/01/2014 - "Here we report on the repeated application of catumaxomab in 2 patients with advanced signet cell gastric cancer. "
11/01/2010 - "OS showed a positive trend for the catumaxomab group and, in a prospectively planned analysis, was significantly prolonged in patients with gastric cancer (n = 66; 71 versus 44 days; p = 0.0313). "
09/01/2008 - "Catumaxomab is a promising approach in the treatment of patients with gastric cancer."
|1.||tumor-associated antigen GA733
|3.||Epidermal Growth Factor Receptor (EGF Receptor)
|7.||Interleukin 1 Receptor Antagonist Protein (Anakinra)
|9.||Succinic Acid (Succinate)
|1.||Drug Therapy (Chemotherapy)